BerGenBio ASA - Correction, new share capital and warrants registered

Report this content

Bergen 22 June 2023: Reference is made to the stock exchange announcement by BerGenBio ASA (the "Company") on 14 June 2023 regarding the final results of the partially underwritten rights issue of 2,500,000,000 new shares in the Company (the "Offer Shares") at a subscription price of NOK 0.10 per new share, raising gross proceeds of NOK 250 million (the "Rights Issue"). In addition, the subscribers in the Rights Issue were allocated one warrant for every two Offer Shares allocated to them and paid by them in the Rights Issue (the "Warrants"). The Rights Issue resulted in the issuance of 1,249,999,617 Warrants.

The Warrants and the share capital increase relating to the Rights Issue is now registered with the Norwegian Register of Business Enterprises. After this, the Company's new registered share capital is NOK 258,866,053.20 divided into 2,588,660,532 shares, each with a nominal value of NOK 0.10.


The Offer Shares and the Warrants are expected to be delivered to investors on 23 June 2023, however trading in the Offer Shares on Oslo Børs with ordinary T+2 settlement may accordingly commence now.


For further information, please contact:


Martin Olin CEO, BerGenBio ASA


Rune Skeie, CFO, BerGenBio ASA



About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate bemcentinib a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and severe respiratory infections.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The Company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit


This information is published in accordance with the requirements of the Oslo Rule Book II and is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.